retatrutide ly3437943 clinical trial results (LY3437943) Injector Pen | Triple Agonist Research Peptide Retatrutide Phase 2: Type 2

A few posters wrote that they have heard about carnitine fishy body odor but hadn't experienced it themselves

Phase 2 trial dosing used once-weekly subcutaneous injections with gradual escalation from 1 mg up to 12 mg to minimise gastrointestinal side effects

The absence of pharmacokinetic studies, dose-response relationships, or comparative effectiveness data represents a significant evidence gap

4) If symptoms occur, stop consumption and consult a doctor or contact customer service

A maximum-tolerated dose was not identified

If you have localized abnormal sensations in your skin burning, tingling, electric feelings that's dysesthesia